Basic, translational and clinical research
Cancer is a group of diseases driven by inherently nanostructural problems. As such, there are obvious benefits to treatments employing nanoscale structures and processes. Cancer Nanotechnology aims to provide a forum so that the most promising emerging themes should be pre-eminent in the minds of researchers working in one—or, indeed, both—of the disciplines of cancer research or nanotechnology.
Read our Editorial to learn more
Cancer Nanotechnology accepted for inclusion in SCIE
We are delighted to announce that Cancer Nanotechnology has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics.
Starting 2020, Cancer Nanotechnology will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score and Journal Impact Factor.
We would like to thank everyone for supporting Cancer Nanotechnology and contributing to this success.
Stay up to date
Do you want to stay up to date on the latest from Cancer Nanotechnology? Sign up for article alerts and news from this journal in order to receive updates for recently published articles, as well as news about Cancer Nanotechnology and BMC.
Part of the BMC family
Cancer Nanotechnology is now part of the BMC family of journals. The BMC website receives over 100 million views per year and is a pioneer of open access publishing. Bookmark the new URL and sign up to article alerts to stay up-to-date about what's happening in Cancer Nanotechnology.
2018 Journal Metrics
52 days to first decision for reviewed manuscripts only
47 days to first decision for all manuscripts
160 days from submission to acceptance
23 days from acceptance to publication
52 Altmetric mentions
- ISSN: 1868-6966 (electronic)
- ISSN: 1868-6958 (print)